-
Tytuł:
-
In-octreotide SPECT/CT and conventional imaging.
-
Autorzy:
-
Yamaga LYI; Imaging Department, Hospital Israelita Albert Einstein, Av. Albert Einstein, 627, São Paulo, 05651-901, Brazil. .; Rua Jose Maximo Monteiro de Oliveira, 196, Parque dos Príncipes, Osasco, São Paulo, CEP 06030-362, Brazil. .
Cunha ML; Imaging Department, Hospital Israelita Albert Einstein, Av. Albert Einstein, 627, São Paulo, 05651-901, Brazil.
Campos Neto GC; Imaging Department, Hospital Israelita Albert Einstein, Av. Albert Einstein, 627, São Paulo, 05651-901, Brazil.
Garcia MRT; Imaging Department, Hospital Israelita Albert Einstein, Av. Albert Einstein, 627, São Paulo, 05651-901, Brazil.
Yang JH; Multiple Neoplasia Outpatiet Clinic, Universidade Federal de São Paulo, São Paulo, Brazil.
Camacho CP; Multiple Neoplasia Outpatiet Clinic, Universidade Federal de São Paulo, São Paulo, Brazil.
Wagner J; Imaging Department, Hospital Israelita Albert Einstein, Av. Albert Einstein, 627, São Paulo, 05651-901, Brazil.
Funari MBG; Imaging Department, Hospital Israelita Albert Einstein, Av. Albert Einstein, 627, São Paulo, 05651-901, Brazil.
-
Źródło:
-
European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2017 Sep; Vol. 44 (10), pp. 1695-1701. Date of Electronic Publication: 2017 Apr 20.
-
Typ publikacji:
-
Clinical Trial; Comparative Study; Journal Article
-
Język:
-
English
-
Imprint Name(s):
-
Original Publication: Berlin : Springer-Verlag Berlin, 2002-
-
MeSH Terms:
-
Organometallic Compounds*
Carcinoma, Neuroendocrine/*drug therapy
Octreotide/*analogs & derivatives
Single Photon Emission Computed Tomography Computed Tomography/*methods
Thyroid Neoplasms/*drug therapy
Adult ; Aged ; Female ; Humans ; Male ; Middle Aged ; Recurrence ; Young Adult
-
References:
-
Thyroid. 2015 Jun;25(6):567-610. (PMID: 25810047)
Nucl Med Commun. 2012 Jul;33(7):766-74. (PMID: 22531829)
Clin Endocrinol (Oxf). 2001 May;54(5):641-9. (PMID: 11380495)
J Nucl Med. 2007 Apr;48(4):508-18. (PMID: 17401086)
Eur J Nucl Med. 2001 Jan;28(1):64-71. (PMID: 11202454)
Metabolism. 1992 Sep;41(9 Suppl 2):104-10. (PMID: 1355582)
Biomed Pharmacother. 2008 Mar;62(3):139-46. (PMID: 17892924)
J Nucl Med. 2011 Dec;52(12 ):1855-63. (PMID: 22052128)
J Nucl Med. 2010 May;51(5):704-12. (PMID: 20395333)
J Nucl Med. 2003 May;44(5):708-16. (PMID: 12732671)
Endocrine. 2012 Dec;42(3):535-45. (PMID: 22527889)
Clin Endocrinol (Oxf). 1995 Jan;42(1):31-7. (PMID: 7889629)
Cancer. 2000 Mar 1;88(5):1139-48. (PMID: 10699905)
J Nucl Med. 1996 Jun;37(6):912-6. (PMID: 8683310)
Eur J Nucl Med. 1998 Nov;25(11):1482-8. (PMID: 9799343)
Eur J Nucl Med Mol Imaging. 2010 Jan;37(1):49-57. (PMID: 19662413)
Semin Nucl Med. 2005 Jul;35(3):176-85. (PMID: 16098291)
Eur J Nucl Med Mol Imaging. 2012 Apr;39(4):569-80. (PMID: 22223169)
J Clin Endocrinol Metab. 2007 Nov;92 (11):4185-90. (PMID: 17726071)
Nat Clin Pract Endocrinol Metab. 2008 Jan;4(1):22-32. (PMID: 18084343)
Eur J Nucl Med. 2000 Mar;27(3):273-82. (PMID: 10774879)
Eur J Nucl Med Mol Imaging. 2009 Aug;36(8):1265-72. (PMID: 19266197)
Eur Radiol. 2016 Mar;26(3):900-9. (PMID: 26162577)
J Clin Endocrinol Metab. 1993 Jun;76(6):1413-7. (PMID: 8501144)
J Nucl Med. 2010 Jun;51(6):875-82. (PMID: 20484441)
AJR Am J Roentgenol. 2013 Dec;201(6):W867-76. (PMID: 24261394)
-
Contributed Indexing:
-
Keywords: 111In-octreotide; 68Ga-DOTATATE; Medullary thyroid carcinoma; Positron emission tomography
-
Substance Nomenclature:
-
0 (Organometallic Compounds)
0 (indium-111-octreotide)
9L17Y0H71P (gallium Ga 68 dotatate)
RWM8CCW8GP (Octreotide)
-
SCR Disease Name:
-
Thyroid cancer, medullary
-
Entry Date(s):
-
Date Created: 20170422 Date Completed: 20180314 Latest Revision: 20220316
-
Update Code:
-
20240105
-
DOI:
-
10.1007/s00259-017-3701-9
-
PMID:
-
28429044
-
Purpose: The aim of this study was to prospectively compare the detection rate of 68 Ga-DOTATATE PET-CT with 111 In-octreotide SPECT-CT and conventional imaging (CI) in medullary thyroid carcinoma (MTC) patients with increased calcitonin (Ctn) levels but negative CI after thyroidectomy.
Methods: Fifteen patients with raised Ctn levels and/or CI evidence of recurrence underwent 68 Ga-DOTATATE PET-CT, 111 In-octreotide SPECT-CT and CI. Histopathology, CI and biochemical/clinical/imaging follow-up were used as the reference standard. PET/CT, SPECT/CT and CI were compared in a lesion-based and organ-based analysis.
Results: PET/CT evidenced recurrence in 14 of 15 patients. There were 13 true positive (TP), 1 true negative (TN), 1 false positive (FP) and no false negative (FN) cases, resulting in a sensitivity and accuracy of 100% and 93%. SPECT/CT was positive in 6 of 15 cases. There were 6 TP, 2 TN, 7 FN and no FP cases, resulting in a sensitivity of 46% and accuracy of 53%. CI procedures detected tumor lesions in 14 of 15 patients. There were 13 TP, 1TN, 1 FP and no FN cases with a sensitivity of 100% and accuracy of 93%. A significantly higher number of lesions was detected by PET/CT (112 lesions, p = 0.005) and CI (109 lesions, p = 0.005) in comparison to SPECT/CT (16 lesions). There was no significant difference between PET/CT and CI for the total number of detected lesions (p = 0.734). PET/CT detected more lesions than SPECT/CT regardless of the organ. PET/CT detected more bone lesions but missed some neck nodal metastases evidenced by CI. The number of lesions per region demonstrated by PET/CT and CI were similar in the other sites.
Conclusion: 68 Ga-DOTATATE PET/CT is superior to 111 In-octreotide SPECT/CT for the detection of recurrent MTC demonstrating a significantly higher number of lesions. 68 Ga-DOTATATE PET/CT showed a superior detection rate compared to CI in demonstrating bone metastases.
Comment in: Eur J Nucl Med Mol Imaging. 2017 Sep;44(10 ):1692-1694. (PMID: 28638977)